Stockreport

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Lyell Immunopharma, Inc.  (LYEL) 
PDF Expect to share initial clinical and translational data from the Phase 1 trial of LYL797, a ROR1-targeted CAR T-cell product candidate, this quarterOn track to report in [Read more]